What is a medical device under mdr 2017 245

Navigating the complexities of the European Union's Medical Device Regulation (MDR) requires a precise understanding of what constitutes a "medical device" under the new legal framework established by Regulation (EU) 2017/745. This comprehensive update has fundamentally altered how manufacturers classify, assess risk, and place their products on the market, ensuring that only devices meeting rigorous standards for safety and performance reach patients. For industry professionals and regulatory affairs specialists, deciphering these definitions is the critical first step toward successful compliance.

The Core Definition and Scope of Application

At the heart of the MDR lies a rigorous definition designed to exclude specific items while capturing the broad spectrum of medical technologies. The regulation explicitly states that a medical device is any instrument, apparatus, appliance, software, implant, reagent, or other article or component intended to be used in conjunction with a device, which does not achieve its primary intended action through pharmacological, immunological, or metabolic means, and which does not attach to the human body for the purpose of treatment or diagnosis, but instead relies on mechanical action. This exclusion of drug-like mechanisms is crucial for determining the correct regulatory path, as it distinguishes true devices from medicinal products. Furthermore, the scope extends to all such devices intended for humans, regardless of whether they are for preventing, diagnosing, monitoring, predicting, prognosing, treating, alleviating, or compensating for a disease, or for supporting or sustaining life, or for investigating, replacing, or modifying anatomy or physiology for a specific purpose.

Essential Requirements and Performance Criteria

Once a product is categorized as a medical device, it must satisfy the essential requirements outlined in Annex I of the MDR. These requirements cover a vast array of areas, including general safety, performance, and post-market surveillance. For instance, the device must not fail to achieve its intended performance when used according to the instructions, and it must not cause harm to the user or other persons, or to the environment, except to the extent that such failure or harm is acceptable. The regulation mandates that the manufacturer must conduct a Risk Management process, typically following the ISO 14971 standard, to identify hazards associated with the device and implement necessary measures to reduce risks to an acceptable level. This systematic approach ensures that the device remains safe throughout its lifecycle, from the initial design phase through to the end of its service life.

The Critical Role of Intended Purpose

One of the most challenging aspects of MDR compliance is determining the "intended purpose" of a device, as this factor heavily influences the classification class (Class I, IIa, IIb, or III) and the applicable regulatory pathway. The intended purpose is not merely the function described in the marketing authorization or technical file but rather the specific reason the manufacturer claims the device is being used by the end-user. If a manufacturer markets a device for multiple purposes, the device is generally classified based on the purpose that carries the highest risk. For example, a wearable fitness tracker intended primarily for health monitoring might fall under a different class than if marketed for diagnostic use. The MDR emphasizes that the intended purpose must be clearly defined in the device's technical documentation and reflected in the instructions for use to avoid ambiguity during the conformity assessment process.

Classification and Conformity Assessment Procedures

The MDR introduces a more granular classification system to ensure that higher-risk devices undergo more stringent scrutiny. Devices are now classified into four classes: Class I (low risk), Class IIa (moderate risk), Class IIb (high risk), and Class III (very high risk). The classification is determined by the degree of risk associated with the device and its intended purpose. Notably, the MDR introduces a new Category III device for "connected health" products and a new Category IV for "life-sustaining" devices, reflecting the evolving nature of modern healthcare technology. The conformity assessment procedures vary significantly based on this classification. Class I devices generally require a Declaration of Conformity, while higher classes require involvement from a Notified Body, which conducts a thorough review of the technical documentation, evaluates the quality management system, and may perform audits before issuing a Certificate of Conformity.

Post-Market Surveillance and Vigilance Obligations

Perhaps the most significant shift in the MDR is the emphasis on post-market surveillance and vigilance. Manufacturers are now legally obligated to monitor the performance of their devices long after they have been placed on the market. This involves collecting data from adverse events reported through the EU Vigilance Database (EUDAMED) and conducting periodic safety updates (PSURs) that must be submitted to notified bodies and national competent authorities. The goal is to continuously monitor the safety and performance of the device throughout its lifecycle and to take immediate corrective or preventive actions if risks are identified. This dynamic regulatory environment ensures that medical devices remain safe and effective even after initial certification, fostering a culture of continuous improvement and patient protection across the European Union.

  • Manufacturers must ensure their Quality Management System (QMS) meets ISO 13485 standards.
  • Technical files must be maintained for a minimum of ten years after the last device is placed on the market.
  • Clinical evaluation must be conducted to substantiate the safety and performance claims of the device.
  • Vigilance data must be reported within 24 hours of first notice of death or serious injury.

By adhering to these principles and understanding the nuances of the MDR 2017/745, pharmaceutical and medical device companies can navigate the regulatory landscape with confidence, ensuring their innovations reach patients while maintaining the highest standards of quality and safety.

Related reading